PDGF receptors, TGF-β receptors, VEGF receptors, and EGF receptors (PDGFR, TGFBR/TβR, VEGFR, EGFR)

Each receptor family is a membrane-bound protein complex that binds to its specific growth factor ligand, triggering intracellular kinase signaling cascades that regulate key cell behaviors—proliferation, migration, differentiation, survival, and angiogenesis. PDGF receptors (PDGFRα and PDGFRβ) bind PDGF isoforms and mediate responses in vascular and connective tissue cells, playing major roles in angiogenesis, wound repair, fibrosis, and cancer stroma. VEGF receptors (VEGFR1, VEGFR2, VEGFR3) are primarily expressed in endothelium, controlling vasculogenesis, angiogenesis, and lymphangiogenesis; critical in cancer and eye disease. TGF-β receptors (TGFBR1/ALK5, TGFBR2, TGFBR3) are serine/threonine kinase receptors that mediate TGF-β signaling: key regulators of immune modulation, epithelial-mesenchymal transition, fibrosis, and cancer. EGF receptors (EGFR/HER1) are ubiquitous tyrosine kinases that, when activated by EGF and related ligands, control epithelial cell growth, differentiation, and survival—heavily implicated in various solid tumors. Due to extensive cross-talk and co-expression, these receptors are often co-targeted or studied together in cancer biology, regenerative medicine, and drug development.

Other names

PDGFRαPDGFRβTGFBR1 (ALK5)TGFBR2TGFBR3 (betaglycan)VEGFR-1 (FLT-1)VEGFR-2 (KDR/FLK-1)VEGFR-3 (FLT-4)ErbB1HER1EGFR

Mechanism of action for drugs targeting these receptors include tyrosine kinase inhibition by small molecules (e.g., sunitinib, imatinib), blockade of ligand-receptor binding by monoclonal antibodies (e.g., bevacizumab, cetuximab), the use of ligand traps/decoys, downregulation of receptor expression, and serine/threonine kinase inhibition (specific to the TGF-β pathway).